# Towards evidence-based medical cannabis

Victor Grech

**Abstract**

Medical cannabis (MC) is at a crossroads. The MC industry needs evidence-based medicine to sell MC as there is still some residual stigma among the medical profession. Furthermore, evidence is needed in order to persuade doctors to prescribe. The requisite papers must be high quality research: double-blind, randomized control trials, systematic reviews and meta-analyses. As it is, MC currently incorporates relatively few commercial products, and those that are developed and marketed with standardized ingredients and with the requisite quality control (e.g. nabilone) have been welcomed by the medical community as they permit proper trials. At the time of writing, evidence for the usefulness of MC is limited and MC is associated with significant side effects. Clearly, new products and more clinical trials are required. Product development and trialing will take time and will cost money. There is a knowledge gap that must be bridged if MC is to ever be treated as medicine and routinely prescribed. MC must meet the same exacting standards of quality, effectiveness and safety of any other prescription drug or it risks being ignored or marginalized by the medical community. For all of these reasons, including the many unanswered questions, the MC industry constitutes an exciting and lucrative opportunity for Malta.

**Victor Grech** PhD (London), PhD (Malta), FRCPCH, FRCP(UK), DCH
Department of Paediatrics
Mater Dei Hospital
Msida
victor.e.grech@gov.mt

## Introduction

Medical cannabis (MC) is at a crossroads just like alcohol during prohibition from 1919 in the United States after the 18th Amendment which banned access to alcohol. Indeed, alcohol was a prescription item, which could be prescribed by doctors for specific indications (figure 1).[1]

***Figure 1**: Prohibition era medicinal alcohol prescription*




## Medical Cannabis

Cannabis is a complex set of compounds (circa 400–500) which include cannabinoids, terpenes and flavonoids. These interact and produce the so-called entourage effect[2] whereby non-psychoactive compounds (mostly cannabidiol - CBD) modulate the psychoactive effects of (mostly) THC (tetrahydrocannabinol).

The MC industry needs evidence-based medicine to sell MC as there is still some residual stigma among the medical profession and evidence is need in order to persuade doctors to prescribe after interacting with medical representative and after exposure to studies in conferences.

The requisite papers must be high quality research: double-blind, randomized control trials (RCT), systematic reviews and meta-analyses. For example, in the UK, the study hierarchy for evidence based medicine is as per table 1.

***Table 1:*** *Evidence-based medicine: study hierarchy, UK (abridged)*

| | |
|---|---|
| 1a: | Systematic reviews of randomized controlled trials. |
| 1b: | Individual randomized controlled trials. |
| 2a: | Systematic reviews of cohort studies. |
| 2b: | Individual cohort study/low quality RCT. |
| 3a: | Systematic review of case-control studies. |
| 3b: | Individual case-control study. |
| 4: | Case series. |
| 5: | Expert opinion. |

The medical profession expects level 1 evidence. Such evidence would further promote MC with the inevitable inclusion in guidelines. For example, the European Societẏs guidelines for the treatment of hypertension are based on, and literally riddled by levels of evidence (figure 2).[2]

***Figure 2:*** *European Society's guidelines for the treatment of hypertension – see levels of evidence and class thereof on the right.*[2]

**Drug treatment strategy for hypertension**

| Recommendations | Class[a] | Level[b] |
|---|---|---|
| Among all antihypertensive drugs, ACE inhibitors, ARBs, beta-blockers, CCBs, and diuretics (thiazides and thiazide-like drugs such as chlorthalidone and indapamide) have demonstrated effective reduction of BP and CV events in RCTs, and thus are indicated as the basis of antihypertensive treatment strategies.[2] | I | A |
| Combination treatment is recommended for most hypertensive patients as initial therapy. Preferred combinations should comprise a RAS blocker (either an ACE inhibitor or an ARB) with a CCB or diuretic. Other combinations of the five major classes can be used.[233,318,327,329,341–345] | I | A |
| It is recommended that beta-blockers are combined with any of the other major drug classes when there are specific clinical situations, e.g. angina, post-myocardial infarction, heart failure, or heart rate control.[300,341] | I | A |
| It is recommended to initiate an antihypertensive treatment with a two-drug combination, preferably in an SPC. Exceptions are frail older patients and those at low risk and with grade 1 hypertension (particularly if SBP is <150 mmHg).[342,346,351] | I | B |
| It is recommended that if BP is not controlled[c] with a two-drug combination, treatment should be increased to a three-drug combination, usually a RAS blocker with a CCB and a thiazide/thiazide-like diuretic, preferably as an SPC.[349,350] | I | A |
| It is recommended that if BP is not controlled[c] with a three-drug combination, treatment should be increased by the addition of spironolactone or, if not tolerated, other diuretics such as amiloride or higher doses of other diuretics, a beta-blocker, or an alpha-blocker.[310] | I | B |
| The combination of two RAS blockers is not recommended.[291,298,299] | III | A |

Another example from the American Pain Society is equally salutary, stating that

> When considering initiation of methadone, … recommends that clinicians perform an individualized medical and behavioral risk evaluation to assess risks and benefits of methadone, given methadone's specific pharmacologic properties and adverse effect profile (strong recommendation, low-quality evidence).[3]

A strong recommendation, low-quality evidence is the least that will be accepted by any doctor as the basis for prescribing a drug. This article will not dwell on the importance of evidence-based medicine as the readers of this journal are fully cognizant of such matters. However, the MC industry is not traditional pharma and may not be aware of the ramifications and requirements for marketing a drug to doctors. The demonstration of non-inferiority of MC to extant treatment, or better still, superiority, is mandatory.

How can this be done? If a suitable product exists, creating the requisite research for a particular indication requires a plethora of disparate skills:

- Create a convincing proposal for a double-blind RCT.
  - Based on exhaustive literature review.
  - Including clear consent forms.
- Apply for ethical approval and data protection approval.
- Find a grant/funding.
- Register the study - internationally.
- Purchase insurance
- Enroll subjects: recruitment, informed consent.
- Run the study.
- Collect the data.
- Analyse it.
- Write a paper draft.
- Present at conferences:
  - A compelling abstract.
  - An attractive poster.
  - A captivating presentation.
- Professionally lay out a paper.
- Know which journals to target.
- Understand journal editors.
- Negotiate the peer-review process.
- Consider open-access publication.

Once several studies are in hand, a systematic review may be carried out e.g. using the PICO framework (**p**atient, **p**roblem or **p**opulation; **i**ntervention; **c**omparison, **c**ontrol or **c**omparator and **o**utcome).[4]

MC currently incorporate relatively few commercial products, and those that are developed and marketed with standardized ingredients and with the requisite quality control (e.g. nabilone) have been welcomed by the medical community as they permit proper RCTs. Thus far however, MC has not been shown to be terribly effective and has been associated with significant side effects.[5]

Clearly, new products and more clinical trials are required, since currently, patients preference for cannabinoids exceeds cannabinoids effectiveness.[6] These will take time and will cost money. For example, for a modelled, pharmaceutical industry-sponsored trial with 20 subjects required:

- Circa 4,012 man hours.
- 17 office visits/patient.
- Circa 200 hours/patient.
- 32% of total hours devoted to nonclinical activities related to
  - Institutional review board submission.
  - Completion of clinical reporting forms.

Thus, excluding overheads, this was estimated to cost circa $6,000 per enrolled subject, including $2,000 devoted to nonclinical costs, and this was back in 2003 with 20 subjects.[7] The reality is that studies are usually far larger. For example, the 2017 CANTOS trial of the anti-inflammatory drug canakinumab (Ilaris, Novartis) enrolled 10,000 cardiovascular high-risk patients.[8]

**Current evidence**

At the time of writing, evidence for the usefulness of MC is limited. For example, a recent (2017) review regarding MC effectiveness for the treatment of pain concluded that

> Evidence for inhaled marijuana for pain is too sparse and poor to provide good

> evidence-based guidance. Synthetic MC-derived products may modestly improve neuropathic pain for one in 11- 14 users but perhaps not for other pain types. Additionally, longer and larger studies (better evidence) show no effect. Adverse events are plentiful.[6]

Besides pain, a recent (2017) review with regard to the effectiveness for treatment of other conditions concluded that

> For most conditions (example anxiety), cannabinoid evidence is sparse (at best), low quality and non-convincing. Dronabinol/nabilone improve control of nausea/vomiting post chemotherapy for 1 in 3 users over placebo. Nabiximols likely improve multiple sclerosis spasticity ≥30% for ~1 in 10 users over placebo.[6]

With regard to epilepsy, a recent (2018) systematic review and meta-analysis on the efficacy and safety of cannabidiol concluded that

> AEs significantly associated with CBD were somnolence, decreased appetite, diarrhea, and increased serum aminotransferases…Adjunctive CBD in patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) experiencing seizures uncontrolled by concomitant anti- epileptic treatment regimens is associated with a greater reduction in seizure frequency and a higher rate of AEs than placebo.[9]

A recent (2018) review of the role of cannabis in the management of inflammatory bowel disease commissioned by the Crohn's and Colitis Foundation noted that

> Human studies have found benefit in controlling symptoms and improving quality of life, but no studies have established true disease modification given the absent improvement in biomarker profiles or endoscopic healing.[10]

**Side effects**

MC is also plagued by a significant risk of adverse effects, which are well known, and unexpected effects also frequently manifest. For example, cannabis use increases risk for revision after total knee arthroplasty.[11]

Another alarming example is that marijuana was found to have induced a Type I Brugada Pattern in a patient in whom this could not later be provoked with procamide challenge.[12] Indeed a recent (2017) review with regard to the harms associated with MC therapy concluded that

> Compared to placebo, medical cannabinoids cause multiple different adverse events in patients, from visual disturbance or hypotension (1 in 3-10) to hallucination or paranoia (1 in 20).
>
> Stopping due to adverse effects occurs in 1 in every 8-20 patients. Regardless of the type of medical cannabinoid used, adverse events are common and likely underestimated. Given the extensive harms, potential benefits must be impressive to warrant a trial of therapy.[13]

Additionally, concern has been raised by the finding that chronic marijuana use predominantly affects brain regions that supervise critical thought processes, such as attention, memory, and social interactions. The authors concluded that

> Disruption of these areas has been documented in schizophrenia and Alzheimer's disease, illnesses with symptoms and brain changes that parallel findings in marijuana abusers. These findings counter the claim that marijuana is a harmless drug and are a cause for alarm in persons with cannabis dependence.[14]

**Conclusion**

Extant data/product/s may not even be representative for the purposes for which MC is sought. There is clearly a knowledge gap must be bridged if MC is to ever be treated as medicine and routinely prescribed. MC must meet the same exacting standards of quality, effectiveness and safety of any other prescription drug or it risks being ignored or marginalized by the medical community. Indeed,

> The medical community assumes a contradictory stance toward medical

> marijuana (MM). Health care providers use the agent clinically…However, most professional medical associations do not offer clinical guidance on the subject, medical practice infrastructure does not always take MM into account, and some physicians who recommend MM clinically acknowledge that they do not understand it well enough to do so.[15]

MC is thus at a crossroads and must decide whether to continue as is, with equivocal studies and remain marginally used, largely a last ditch prescription mostly due to side effects. Or to improve and prove the value of extant and new products with RCTs that will lead to the inclusion of MC in medical society guidelines, ensuring their wider and useful use.

For all of these reasons, including the many unanswered questions, the MC industry constitutes an exciting and lucrative opportunity for Malta.

## References


1. Appel JM. " Physicians are not Bootleggers": The Short, Peculiar Life of the Medicinal Alcohol Movement. Bull Hist Med. 2008 Summer;82(2):355-86
2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis K, Aboyans V, Desormais I; List of authors/Task Force members. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018 Dec;36(12):2284-2309.
3. Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, Inturrisi C, Knight JR, Otis-Green S, Marcus SM, Mehta D, Meyer MC, Portenoy R, Savage S, Strain E, Walsh S, Zeltzer L1 American Pain Society; Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014 Apr;15(4):321-37.
4. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007 Jun 15;7:16.
5. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018 Mar;49:12-19.
6. Alberta College of Family Physicians. Any Other Doobieous Effects of Medical Cannabinoids? Tools for Practice. 2017; December. https://www.acfp.ca/wp-content/uploads/tools-for-practice/1512754221_tfp201medcanotherfv.pdf . Accessed 13/11/18
7. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol. 2003 Nov 15;21(22):4145-50.
8. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 Oct 7;39(38):3499-3507.
9. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs. 2018 Nov 3. doi: 10.1007/s40265-018-0992-5.
10. Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, Buchanan S, Zmeter N, Rubin DT. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn's and Colitis Foundation. Inflamm Bowel Dis. 2018 Oct 24. doi: 10.1093/ibd/izy319.
11. Law TY, Kurowicki J, Rosas S, Sabeh K, Summers S, Hubbard Z, Roche M. Cannabis use increases risk for revision after total knee arthroplasty. J Long Term Eff Med Implants. 2018;28(2):125-130. doi: 10.1615/JLongTermEffMedImplants.2018027401.
12. Kariyanna PT, Jayarangaiah A, Hegde S, Marmur JD, Wengrofsky P, Yacoub M, Post M, McFarlane SI. Marijuana Induced Type I Brugada Pattern: A Case Report. Am J Med Case Rep. 2018;6(7):134-136.
13. Alberta College of Family Physicians. Harms of Medical Cannabinoids: Up in Smoke! Tools for Practice. 2017; December. https://www.acfp.ca/wp-content/uploads/tools-for-practice/1511480622_tfp200harmsmmfv.pdf. Accessed 13/11/18.
14. Stoecker WV, Rapp EE, Malters JM. Marijuana Use in the Era of Changing Cannabis Laws: What Are the Risks? Who is Most at Risk? Mo Med. 2018 Sep-Oct;115(5):398-404.
15. Braun I, Tulsky J. Reconciling the Discrepancies in Medicine's Relationship to Medical Marijuana. Ann Intern Med. 2018;169(9):646-7.


**Cover Picture:**
'Valletta'
*Maltese lace (Bizzilla)*
**By** Sr Therese Bajada

**Review Article**

# Measles is back

Ruth Farrugia, David Pace

**Abstract**

Measles is one of the most deadly vaccine preventable diseases. The incidence of measles, and resultant mortality, had dropped drastically following the introduction of widespread measles immunisation since the 1960s. However, there is currently a worldwide surge in measles cases, with a marked increase over the past 3 years. Measles outbreaks and endemic transmission have been re-established in countries which had previously achieved measles elimination. The rise in measles cases has been mainly attributed to a drop in the recommended two dose vaccination schedule below the 95% uptake threshold necessary for interruption of transmission and sustainment of herd protection. This resurgence of measles is largely a result of the damage done by Andrew Wakefield, who in 1998 incorrectly and maliciously suggested a possible link between the measles, mumps and rubella (MMR) vaccine and autism. Such a possible association has subsequently been disproven by several scientifically robust studies. Still, most cases of measles have occurred in unimmunised individuals, mainly teenagers, who had missed out on vaccination in early childhood, and in infants under one year of age, who are too young to be vaccinated. Measles is highly contagious, with up to 18 people being potentially infected from a single case, so containment measures are important to prevent spread. These include isolation and immediate notification of suspected or confirmed cases, as well as wearing appropriate personal protective equipment when in contact with these patients. Health care professionals have a crucial role in promoting measles immunisation, which is the only rational way of preventing measles.

**Ruth Farrugia*,** MD, MRCPCH (UK), MSc PEM (Edin)
ruth.b.farrugia@gov.mt

**David Pace,** MD, Pg Dip PID (Oxf), FRCPCH, PhD

**Corresponding author*

Measles is one of the most deadly vaccine-preventable diseases[1] and is included in the top overall causes of death in children under 5 years of age worldwide.[2]

Prior to the introduction of widespread measles vaccination in 1963, measles accounted for about 2.6 million deaths annually.[3] In fact, one of the aims of the Global Vaccine Action Plan 2011 – 2020[4] was the elimination of measles in 4 out of 5 World Health Organization (WHO) regions by 2015, but this aim has not been achieved.[5] Measles elimination is defined as the absence of endemic measles virus transmission in a region or other defined geographic area for ≥12 months, in the presence of a high quality surveillance system that meets targets of key performance indicators.[6]

In theory, eradication of measles is possible because humans are the only reservoirs,[7] measles is only infectious during the acute phase,[7] specific and rapid diagnostic tests are available,[8] the measles virus is monotypic[8] and a monovalent vaccine is effective against all known virus isolates.[8]

The measles virus is aerosol-borne and is easily spread by coughing and sneezing, close personal contact or direct contact with infected nasal or throat secretions.[3] Measles is highly contagious, starting from four days prior onset of the rash until four days following rash appearance.[1] Over 90% of contacts develop the disease.[9] The basic reproduction number ($R_0$) for measles lies between 12 and 18,[10] meaning that a single patient with measles may infect up to 18 susceptible people.[9] In comparison, $R_0$ for influenza is estimated between 2 and 4[11] while $R_0$ for varicella ranges between 3.7 and 5.[12]

The clinical description for measles by the Centers for Disease Control and Prevention (CDC) states that measles is an acute illness characterised by a generalised maculopapular rash that is present for at least 3 days, an oral temperature of at least 101℉ (38.3℃) and the presence of cough, coryza, and conjunctivitis.[13] The pathognomonic Koplik spots on the buccal mucosa, which are not always present, are not a diagnostic criterion.[7] The incubation period for measles is 10 days for onset

of fever; the rash usually appears 4 days later.[7] Laboratory diagnosis, which is a requisite for case confirmation, may be performed by detecting measles IgM in serum or saliva.[14] Of note, 30% may be negative in the initial 3 days and the tests should not be performed later than 4 weeks from onset of the rash.[15] False positives may occur especially with rubella and parvovirus B19 infections.[16] PCR testing on respiratory secretions, nasopharyngeal swab, blood or urine may be needed for genetic characterisation of the virus, which can help identify the source of infection.[17] There is no specific treatment for measles.

Measles complications can occur in up to 40% of patients and are more common in high-risk patients.[7] Pneumonia occurs in up to 1 in 16 patients[18] and is the leading cause of measles-associated death.[1] Other complications include otitis media (in about 1 in 12 measles cases)[18], diarrhoea (in about 1 in 12 measles cases),[18] ocular complications and central nervous system manifestations, such as encephalitis (in about 1 in every 1000 - 2000 measles cases)[18] or subacute sclerosing panencephalitis (in about 4 - 11 per 100,000 measles cases).[1] Measles also causes long-lasting memory B and T cell impairment.[19] High-risk patients include immunosuppressed patients (in whom typical signs and symptoms may be absent), patients with Vitamin A deficiency, malnourished patients and travellers.[7] Young infants also have a higher risk of mortality and complications,[7] especially if born to mothers with vaccine-derived immunity or who are infected with HIV.[20] Passive immunity lasts longer in mothers with natural immunity to measles but by 6 months of age less than 5% of all infants retain maternal antibodies.[21]

A proportion of individuals with measles will need hospital admission. Unfortunately, hospital admission is associated with measles transmission,[22] including outbreaks amongst healthcare workers.[23] The cost of delay in diagnosis and the resultant potential exposure is prohibitive, in view of the high infectivity of measles.[24] Patients suspected of having measles should be isolated immediately and measures should be in place to prevent further spread during outbreaks. The virus remains infective for two hours on solid surfaces, which should be borne in mind when decontaminating a room.[25] Infection control measures should be implemented as per local recommendations and respiratory protection by means of N95 or FFP3 (filtering facepiece class 3) mask should be worn when attending to a patient with suspected or confirmed measles,[26] irrespective of the immunity of the healthcare worker to measles. A normal surgical mask should be worn if a FFP is not available – this will still provide a reasonable level of protection.[27]

The only rational way of preventing measles in a population is through vaccination. The MMR (measles, mumps, rubella) vaccine has 99% effectiveness against measles following 2 doses,[28] is well tolerated, safe,[29] and offers long-lasting protection.[30] In fact, measles vaccination is estimated to have prevented 20.4 million deaths between 2000 – 2016.[31] However, in view of the high $R_0$ for measles, a high uptake of at least 95% for both doses is needed in order to eliminate measles from a population and to attain herd protection.[32-33]

In Malta, the first dose of MMR vaccine is administered at 13 months of age, with the second dose being given at 3 to 4 years of age.[34] This is in line with the WHO recommendations that two doses of measles-containing vaccine, such as the MMR vaccine, for countries with low risk of measles should be given at around 12 months of age for the first dose and that the second dose of MMR vaccine should be given at the age when maximum coverage at national level is anticipated.[35] A supplementary dose of measles vaccine is recommended from 6 months of age onwards during measles outbreaks[35]. Any dose of measles vaccine given before 12 months of age should not be counted as part of the series and these children should be revaccinated with 2 doses of the MMR vaccine after 12 months of age.[36]

Unfortunately, measles immunisation rates have dropped globally. During 2017, 85% of children received one dose of measles vaccine by their second birthday, with only 67% receiving the second dose as part of routine immunisation.[37] In Europe, immunisation rates for 2017 were 95% for the first dose and 90% for the second dose.[38] The single most influential factor for the drop in measles vaccine uptake was an article by Dr Andrew Wakefield in The Lancet in 1998,[39] which suggested a potential link between the MMR vaccine and developmental regression and autism, among other conditions. This paper received disproportionate media coverage and caused the biggest public health scare in UK history.[40] Flaws

in research methods were immediately pointed out, including that it was a case series of 12 children without controls and that data collection relied on parent's personal beliefs and recalls.[41] Large epidemiological studies over the years,[42-46] as well as a WHO extensive review[47] and a Cochrane systematic review,[48] have since disproved any links between the MMR vaccine and autism. The UK General Medical Council found that Dr Wakefield had falsified his data and had breached ethical standards in this publication[49] and consequently he was struck off the register because of his serious professional misconduct.[50] The paper was also withdrawn by The Lancet in 2010.[51] However, it is still widely quoted by anti-vaccine campaigners and parents, some of whom remain unsure whom to believe, despite all the robust scientific evidence proving that the MMR vaccine is not associated with autism.[52]

Endemic transmission of measles can be re-established once vaccination rates fall below the elimination threshold.[53] In fact, measles has again become endemic in all five WHO regions during 2018, with the rate of measles being the highest in a decade[54] and continuing to rise by a further 300% during the first quarter of 2019.[55] Over 82,000 people in the WHO European region contracted measles during 2018, with up to 61% needing hospitalisation and 72 deaths in children and adults.[38] This is more than three times as many as in 2017, 15 times as many as in 2016[18] and even surpassed the number of measles cases in the WHO African region in 2018, which totalled 33,879.[56] This figure includes national outbreaks in countries having previously achieved measles elimination, such as The Netherlands[57] and Greece,[58] and also the re-establishment of endemic transmission in countries where measles had been eliminated, as happened in the United Kingdom.[59]

Malta has maintained the status of measles elimination in 2018, because there have not been any cases of measles due to sustained transmission.[60] However, there is an increasing trend in locally acquired measles, rising from 6 cases in 2018[60] to 15 confirmed cases so by April 2019 - 23 cases in adults and 2 cases in children.[61] During 2018, 95.5% of children in Malta received the first dose of MMR and 95% received the second dose of MMR vaccine.[62] This is in contrast to previous years, when immunisation rates in Malta had dropped below the 95% uptake rate (for both doses) needed to prevent disease transmission. In fact, only 91% of children received the first dose of MMR vaccine and 83% received the second dose during 2017[63], although this could be a result of inadequate notification. This is the ideal scenario for breakthrough cases of measles and, in the absence of herd protection, the potential for outbreaks, as has happened in other countries.

Indeed, the surge in measles in Europe has been mainly attributed to a drop in two-dose measles vaccine coverage below 95% and a drop in prevalence of individuals with vaccine-induced protection of measles to less than 94.4%.[64] Out of the 14,400 reported cases of measles in Europe in 2017[65] with known vaccination status, 87% were unimmunised, 8% had received one dose of measles-containing vaccine, 3% had received two or more doses of vaccine and 2% were vaccinated with an unknown number of doses.[66] Immunisation status was unknown for 6%.[66] Thirty seven percent of measles occurred in children under 5 years of age, with the highest disease burden occurring in children below the age of 1 year, while 45% occurred in patients older that fifteen years.[66] Therefore, nearly half of the measles cases in Europe occurred in unimmunised adolescents aged 15 years or older, highlighting the need to identify and catch-up those who missed out on routine vaccination in childhood.

The resurgence of measles at a global level is being driven by multiple factors, including conflict, poor health education, lack of access to health care, complacency, increasing vaccine hesitancy and low support amongst medical personnel.[67] In addition, vaccine coverage may be suboptimal in at-risk groups, including Roma, Irish travellers, orthodox religious communities[67] and adolescent and adult migrants, who might be excluded from the immunisation catch-up initiatives provided to younger children.[68] Failure to address vaccination shortfalls in vulnerable populations will create immunisation gaps and lead to subnational coverage.

Measles is a vaccine-preventable disease which carries a high morbidity and mortality. Elimination of measles is dependent on sustaining herd protection and in limiting transmission during outbreaks. Our role as health care professionals is to actively encourage MMR vaccine uptake, including opportunistic vaccination for those who were not immunised at the appropriate times, address public

concerns, expedite the diagnosis of measles, notify immediately any suspected or confirmed cases and help in containing outbreaks.

## References


1. Buchanan R, Bonthius D. Measles virus and associated central nervous system sequelae. Seminars in paediatric neurology. 2012;19(3):107-4.
2. World Health Organization. Global Health Observatory data: Causes of Child Mortality, 2017. [Internet]. 2018 [cited 8th April 2019]. Available from: https://www.who.int/gho/child_health/mortality/causes/en/
3. World Health Organization. Measles Fact Sheet. [Internet]. 2018 [cited 28th March 2019];Nov 29. Available from: https://www.who.int/news-room/fact-sheets/detail/measles
4. World Health Organization. Global Vaccine Action Plan 2011 – 2020. [Internet]. 2013 [cited 8th April 2019]. Available from: https://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/
5. World Health Organization Resolution. Renewed commitment to elimination of measles and rubella and prevention of congenital rubella syndrome by 2015 and sustained support for polio-free status in the WHO European region. WHO Regional Office for Europe, Moscow, Russia. [Internet]. 2010 [cited 8th April 2019]. Available from: http://www. euro.who.int/__data/assets/pdf_file/0016/122236/RC60_eRes12. pdf
6. World Health Organization. Monitoring progress towards measles elimination. Weekly epidemiological record. 2010;85:489-96.
7. Moss WJ, Griffin DE. Measles. Lancet. 2012;379:153-164.
8. Meissner HC, Sterbel PM, Orenstien WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics. 2004;114:1065-1069.
9. Holzmann H, Hengel H et al. Eradication of measles: remaining challenges. Medical Microbiology and Immunology. 2016;March 2:1-8.
10. Guerra FM, Bolotin S et al. The basic reproduction number (R0) of measles: a systematic review. Lancet Infectious Diseases. 2017;17(12), e420–e428.
11. Scarbrough Lefebre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into the basic elements. Human Vaccines and Immuotherapeutics. 2015;11(9):2142-2157.
12. Marangi L, Mirinaviciute G et al. The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster. PLoS ONE 2017;12(5):e0176845.
13. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDAA): Measles/Rubeola 2013 Case Definition [Internet]. 2013 [cited 8th April 2019]. Available from: https://wwwn.cdc.gov/nndss/conditions/measles/case-definition/2013/
14. Bellini WJ, Hefland RF. The challenges and strategies for laboratory diagnosis of measles in an international setting. Journal of Infectious Diseases. 2003;187(Suppl 1):S283-90.
15. Hefland RF, Kebede S et al. The effect of timing of sample collection on the detection of measles-specific IgM in serum and oral fluid samples after primary measles vaccination. Epidemiology and Infection. 1999;12(3):451-5.
16. Brown DWG, Ramsay MB et al. Salivary diagnosis of measles: A study of notified cases in the United Kingdom, 1991-1993. British Medical Journal. 1994;308(6395):1015-7.
17. Rota PA, Liffick SL et al. Molecular epidemiology of measles viruses in the United States, 1997-2001. Emerging Infectious Diseases. [Internet]. 2002 [cited 8th May 2016];8(9):902-908. Available online: http://wwwnc.cdc.gov/eid/article/8/9/02-0206_article
18. Oxford Vaccine Group. Vaccine Knowledge Project: Measles. [Internet]. 2019 [cited 1st April 2019]; Mar 7. Available from: http://vk.ovg.ox.ac.uk/measles
19. Mina MJ, Metcalf CJE et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348(6235):694-9.
20. Perry RT, Mmiro F et al. Measles infection in HIV-infected African infants. Annals of the New York Academy of Sciences. 2000;918:377-380.
21. Leuridan E, Hens N et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. British Medical Journal. 2010;340:c1626.
22. Hungerford D, Cleary P et al. Risk factors for transmission of measles during an outbreak: matched case-control study. Journal of Hospital Infection. 2014;86:138-43.
23. Duarte S. Practice what you preach: measles vaccination coverage and outbreaks in healthcare workers in Europe. European Journal of Public Health. 2018(28:4):381-382.
24. Helmecke MR, Elmendorf SL et al. Measles investigation: a moving target. American Journal of Infection Control. 2014;42:911-5.
25. Ritcher S, Hawkins A, Painter L. Measles on the rise: academic institutions be prepared. Perspectives in Learning: A Journal of the College of Education & Health Professions. [Internet]. 2012 [cited 1st April 2019];13(1):33-38. Available online: https://perspectives.columbusstate.edu/v13_i_1/MeaslesOnTheRise.pdf
26. European Centre for Disease Prevention and Control. Safe use of personal protective equipment in the treatment of infectious diseases of high consequence – version 2 [Internet]. 2014 [cited 8th April 2019];Dec 2. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/safe-use-of-ppe.pdf

27. Office of the Superintendent of Public Health. Letter to doctors [Internet]. 2018 [cited 8th April 2019]; Aug 1. Available from: https://deputyprimeminister.gov.mt/en/administration-and-communication/Documents/Circulars/Measles_Doctors_03.08.01.pdf
28. Pillsbury A, Quinn H. An assessment of measles vaccine effectiveness, Australia, 2006-2012. Western Pacific Surveillance and Response. 2015;6(3);43-50.
29. Klein NP, Lewis E et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015;135(2):2321-329.
30. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. The New England Journal of Medicine. 2007;357:1903-1915.
31. Dabbagh A, Patel MK et al. Progress towards regional measles elimination - worldwide 2010 – 2016. Morbidity and Mortality Weekly Report; US Department of Health and Human Services/Centers for Disease Control and Prevention. 2017;66(42):1148-1153.
32. van Boven M, Kretzschmar M et al. Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. Journal of the Royal Society Interface. 2010;7(52):1537-1544.
33. Glick M. Vaccine hesitancy and unfalsifiability. Journal of the American Dental Association. 2015;146(7):491-493.
34. Primary Health Care. National Immunisation Schedule 2017 [Internet]. 2017 [cited 8th April 2019]. Available from: https://deputyprimeminister.gov.mt/en/phc/pchyhi/Pages/National-Immunisation-Schedule.aspx
35. World Health Organization. Summary of the WHO position on measles vaccine – April 2017 [Internet]. 2017 [cited 8th April 2019]. Available from: https://www.who.int/immunization/policy/position_papers/WHO_PP_measles_vaccine_summary_2017.pdf?ua=1
36. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases: measles [Internet]. Updated 2015 [cited 8th April 2019]; July 24. Available grom: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html
37. World Health Organization. Immunization Coverage [Internet]. 2018 [cited 8th April 2019]; July 16. Available from: https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage
38. World Health Organization. Measles in Europe: record number of both sick and immunized. [Internet]. 2019 [cited 28th March 2019]; Feb 7. Available from: http://www.euro.who.int/en/media-centre/sections/press-releases/2019/measles-in-europe-record-number-of-both-sick-and-immunized
39. Wakefield AJ, Murch SH et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. The Lancet. 1998;351:637-41.
40. Kmietowicz Z. Wakefield is struck off for the 'serious and wide-ranging findings against him'. British Medical Journal. 2010;340:c2803.
41. Payne C, Mason B. Autism, inflammatory bowel disease, and MMR vaccine. Lancet. 1998;351:907.
42. Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. British Medical Journal. 2002;325:419-21.
43. Madsen KM, Hviid A et al. A population-based study of measles, mumps and rubella vaccination and autism. New England Journal of Medicine. 2002;347(19):1477-1482.
44. Taylor B, Miller E et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. British Medical Journal. 2002;324(7334):393–396.
45. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. Journal of Child Psychology and Psychiatry. 2005;46(6):572-579.
46. Hornig M, Briese T et al. Lack of Association between Measles Virus Vaccine and Autism with Enteropathy: A Case-Control Study. PLoS ONE 3(9): e3140.
47. World Health Organization. MMR and Autism. Weekly epidemiological record. 2003;78:18.
48. Demicheli V, Rivetti A et al. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews. 2012, Issue 2, Art. No: CD004407.
49. "General Medical Council, Fitness to Practise Panel Hearing, 28 January 2010, Andrew Wakefield, John Walker Smith, Simon Murch". [Internet]. General Medical Council. 2010 [cited 8th April 2019], January 28. Available from: https://briandeer.com/solved/gmc-charge-sheet.pdf
50. "General Medical Council, Fitness to Practise Panel Hearing, 24 May 2010, Andrew Wakefield, Determination of Serious Professional Misconduct". [Internet]. General Medical Council. 2010 [cited 8th April 2019], May 24. Available from: https://web.archive.org/web/20110809092833/http://www.gmc-uk.org/Wakefield_SPM_and_SANCTION.pdf_32595267.pdf
51. The editors of the Lancet. Retraction - Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 2010;375:445.
52. Hilton S, Petticrew M, Hunt K. Parents' champions vs. vested interests: Who do parents believe about MMR? A qualitative study. BMC Public Health. 2007;7:42.
53. Bester JC. Measles and measles vaccination – a review. JAMA Pediatrics. 2016(Oct 3):E1-E7.
54. World Health Organization. 2018 Assessment report of the global vaccine action plan. [Internet]. 2018 [cited 1st April 2019]. Available from: https://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2018_EN.pdf?ua=1
55. World Health Organization. New measles surveillance data for 2019. [Internet]. 2019 [cited 15th April 2019]; Apr 15. Available from: https://www.who.int/immunization/newsroom/measles-data-2019/en/

56. United Nations. Measles cases nearly doubled in a year, UN health agency projects. [Internet]. 2019 [cited 28th March 2019]; Feb 14. Available from: https://news.un.org/en/story/2019/02/1032771
57. Knol M, Urbanus A et al. Large ongoing measles outbreak in a religious community in the Netherlands since May 2013. Euro Surveillance. 2013;18(36):20580.
58. Georgakopoulou T, Horefti E et al. Ongoing measles outbreak in Greece related to the recent European-wide epidemic. Epidemiology and Infection.2018;147(13):1692-8.
59. Measles once again endemic in the United Kingdom. Euro Surveillance. 2008;13(27):18919.
60. Superintenence of Public Health. Press release PR190563 [Internet]. 2019 [cited 28th march 2019]; Mar 19. Available from: https://www.gov.mt/en/Government/DOI/Press%20Releases/Pages/2019/March/19/pr190563.aspx
61. Office of the Superintendent of Public Health, Malta. Information sheet measles [email]. 2019; April 26.
62. Data obtained from National Immunisation Programme, Floriana. Personal communication with Dr Victoria Farrugia Sant'Angelo. 2019; April 29.
63. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2018 global summary. [Internet]. 2018 [cited 8th April 2019];Oct 22. Available from: https://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=MLT#
64. Plans-Rubio P. Why does measles persist in Europe? European Journal of Clinical Microbiology and Infectious Diseases. 2017;Oct;36(10):1899-1906.
65. European Centre for Disease Prevention and Control. Measles and rubella surveillance – 2017. [Internet]. 2018 [cited 28th March 2019]; Apr 23. Available from: https://ecdc.europa.eu/en/publications-data/annual-measles-and-rubella-monitoring-report-2017
66. European Centre for Disease Prevention and Control. Risk of measles transmission in the EU/EAA. [Internet]. 2018 [cited 28th March 2019]; March 23. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Measles-rapid-risk-assessment-European-Union-countries_0.pdf
67. Williams GA, Bacci S et al. Measles among migrants in the European Union and the European Economic Area. Scandinavian Journal of Public Health. 2016;44:6-13.
68. Hargreaves S, Nellums LB et al. Who is responsible for the vaccination of migrants in Europe? Lancet. 2018;391(10132):1752-4.